Q Chip receives $3M of funding; Vyteris merges with MediSync

> Q Chip, a Cardiff, Wales-based company developing sustained release injectable depot formulations, has reached the first close of $3 million of a planned $4.6 million funding round. The money will go toward scale-up of its Q-Sphera technology Q-Chip has raised about $11.5 million to date. Q Chip release

> Vyteris, a New Jersey-based drug-delivery technology company, has taken on MediSync BioServices as a wholly owned subsidiary. MediSync’s specialty is product development, clinical trial management, and data management services for the biotech industry. Vyteris release

> Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies. Report

> A Czech on progress in drug delivery. Radio Report

Drug delivery patent application of the week: Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye. Application